Skip to search formSkip to main contentSkip to account menu

30 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaler [Tudorza]

Known as: ACLIDINIUM BROMIDE 400 ug RESPIRATORY (INHALATION) INHALANT [Tudorza Pressair]_#1, 30 ACTUAT Tudorza 0.4 MG/ACTUAT Dry Powder Inhaler, Tudorza Pressair 400 MCG/INHAL Dry Powder Inhaler, 30 ACTUAT 
National Institutes of Health

Related topics

Related topics

5 relations
Dry Powder InhalerLactose MonohydrateTudorzaaclidinium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Duaklir Pressair: another LAMA/LABA inhaler for COPD.
2019
2019
NEW DRUG APPROVALS Duaklir Pressair for COPD
  • 2019
  • Corpus ID: 180261643
NEW DRUG APPROVALS Duaklir Pressair for COPD The FDA has approved aclidinium bromide/formoterol fumarate (Duaklir Pressair… 
Review
2017
Review
2017
Evaluation of COPD Treatments: A Multicriteria Decision Analysis of Aclidinium and Tiotropium in the United States.
Review
2017
Review
2017
Umeclidinium (Incruse Ellipta) for COPD.
Umeclidinium is a relatively safe medication with few systemic adverse effects. As with aclidinium (Tudorza Pressair… 
Review
2014
Review
2014
Clinical use of aclidinium in patients with COPD
Chronic obstructive pulmonary disease (COPD) is the sixth-leading cause of death in the US. The Global initiative for Chronic… 
2012
2012
Tudorza Pressair (Aclidinium bromide)
New combination: FDA approved aclidinium bromide (Tudorza Pressair, Forest) for the long-term maintenance treatment of… 
Review
2012
Review
2012
Aclidium bromide (Tudorza Pressair) for COPD.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)